View Archive »
About The Cover
The cover for issue 94 of Oncotarget features Figure 6, "Progression free survival in LOH-high and LOH-low groups with operated patients censored at time of potentially curative surgery," by Smyth, et al.
|
|
Table of Contents
Editorial
|
| PRMT5 inhibitors on the myeloma road |
|
https://doi.org/10.18632/oncotarget.26392
|
| 36646-36647 |
|
| The dual effect of pharmacological ascorbate on radiation: The best of both worlds |
|
https://doi.org/10.18632/oncotarget.26396
|
| 36648-36649 |
|
| Prostate cancer genomics and racial health disparity |
|
https://doi.org/10.18632/oncotarget.26399
|
| 36650-36651 |
|
| Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management |
|
https://doi.org/10.18632/oncotarget.26413
|
| 36652-36653 |
Research Papers
|
| Genomic loss of heterozygosity and survival in the REAL3 trial |
|
https://doi.org/10.18632/oncotarget.26336
|
| 36654-36665 |
|
| Modulation of doublestranded RNA pattern recognition receptor signaling in ovarian cancer cells promotes inflammatory queues |
|
https://doi.org/10.18632/oncotarget.26378
|
| 36666-36683 |
|
| SOX2 haploinsufficiency promotes impaired vision at advanced age |
|
https://doi.org/10.18632/oncotarget.26393
|
| 36684-36692 |
|
| Exploiting the transcriptional specificity of the alphamethylacylCoA racemase AMACR promoter for the molecular imaging of prostate cancer |
|
https://doi.org/10.18632/oncotarget.26401
|
| 36693-36704 |
Reviews
|
| Protein arginine methyltransferase 5 PRMT5 dysregulation in cancer |
|
https://doi.org/10.18632/oncotarget.26404
|
| 36705-36718 |
Corrections
|
| Correction: Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height |
|
https://doi.org/10.18632/oncotarget.26429
|
| 36719-36719 |
|
| Correction 2: Everolimus EVE and exemestane EXE in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study |
|
https://doi.org/10.18632/oncotarget.26431
|
| 36720-36721 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC